Head and Neck Surgery Center of Florida, Florida Hospital Celebration Health, USA.
JAMA Otolaryngol Head Neck Surg. 2013 Aug 1;139(8):773-8. doi: 10.1001/jamaoto.2013.3866.
Surgical salvage may be the only viable treatment option for recurrent tumors of the oropharynx. To our knowledge, there have been no published reports directly comparing the oncologic and functional outcomes of patients with recurrent oropharyngeal squamous cell carcinoma (SCC) treated with transoral robotic-assisted surgery (TORS) with those treated with traditional open surgical approaches.
To compare the oncologic and functional outcomes of patients with recurrent oropharyngeal SCC treated with TORS with those treated with traditional open surgical approaches.
Retrospective multi-institutional case-control study; study dates, March 2003 through October 2011.
Four tertiary care institutions (University of Alabama at Birmingham; M. D. Anderson Cancer Center, Houston, Texas; Mayo Clinic, Rochester, Minnesota; and Henry Ford Hospital, Detroit, Michigan). PARTICIPANTS Sixty-four patients who underwent salvage TORS for recurrent oropharyngeal SCC were matched by TNM stage to 64 patients who underwent open salvage resection. INTERVENTION OR EXPOSURE: Salvage TORS for recurrent SCC of the oropharynx.
Patient demographics, operative data, functional, and oncologic outcomes were recorded and compared with a similarly TNM-matched patient group that underwent salvage surgical resection by traditional open surgical approaches. RESULTS Patients treated with TORS were found to have a significantly lower incidence of tracheostomy use (n = 14 vs n = 50; P < .001), feeding tube use (n = 23 vs n = 48; P < .001), shorter overall hospital stays (3.8 days vs 8.0 days; P < .001), decreased operative time (111 minutes vs 350 minutes; P < .001), less blood loss (49 mL vs 331 mL; P < .001), and significantly decreased incidence of positive margins (n = 6 vs n = 19; P = .007). The 2-year recurrence-free survival rate was significantly higher in the TORS group than in the open approach group (74% and 43%, respectively) (P = .01).
This study demonstrates that TORS offers an alternative surgical approach to recurrent tumors of the oropharynx with acceptable oncologic outcomes and better functional outcomes than traditional open surgical approaches. This adds to the growing amount of clinical evidence to support the use of TORS in selected patients with recurrent oropharyngeal SCC as a feasible and oncologically sound method of treatment.
手术挽救可能是复发性口咽肿瘤唯一可行的治疗选择。据我们所知,目前还没有发表的文献直接比较接受经口机器人辅助手术(TORS)治疗和接受传统开放性手术治疗的复发性口咽鳞状细胞癌(SCC)患者的肿瘤学和功能结局。
比较接受 TORS 治疗的复发性口咽 SCC 患者与接受传统开放性手术治疗的患者的肿瘤学和功能结局。
回顾性多机构病例对照研究;研究日期为 2003 年 3 月至 2011 年 10 月。
四个三级保健机构(阿拉巴马大学伯明翰分校;德克萨斯州休斯顿的 M. D. 安德森癌症中心;明尼苏达州罗切斯特的梅奥诊所;密歇根州底特律的亨利福特医院)。
64 例接受复发性口咽 SCC 挽救性 TORS 治疗的患者按 TNM 分期与 64 例接受开放性挽救性切除术的患者相匹配。
复发性口咽 SCC 的挽救性 TORS。
记录患者的人口统计学资料、手术数据、功能和肿瘤学结果,并与接受传统开放性手术治疗的具有相似 TNM 匹配的患者组进行比较。
与接受 TORS 治疗的患者相比,接受气管造口术(n = 14 与 n = 50;P < 0.001)、饲管(n = 23 与 n = 48;P < 0.001)、总住院时间(3.8 天与 8.0 天;P < 0.001)、手术时间(111 分钟与 350 分钟;P < 0.001)、出血量(49 毫升与 331 毫升;P < 0.001)和切缘阳性率(n = 6 与 n = 19;P = 0.007)均显著降低。TORS 组 2 年无复发生存率明显高于开放性手术组(分别为 74%和 43%)(P = 0.01)。
本研究表明,TORS 为复发性口咽肿瘤提供了一种替代的手术方法,其肿瘤学结果可接受,功能结果优于传统开放性手术方法。这增加了越来越多的临床证据,支持在选择的复发性口咽 SCC 患者中使用 TORS,作为一种可行且具有肿瘤学意义的治疗方法。